Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)

Abstract

Background: Zervimesine (CT1812) is an experimental oral, small‐molecule drug candidate in development for Alzheimer’s disease and dementia with Lewy bodies (DLB). Zervimesine is designed to protect neurons by preventing the binding of oligomers of pathogenic proteins including β‐amyloid and ɑ‐synuclein.

The paper